Targeted Immunotherapy for Cancer


Cytovation builds on 16 years of cutting-edge research from two leading Norwegian institutions: University of Bergen and Haukeland University Hospital. The company is led by an experienced team and world-renowned experts in tumour biology, with close to €15 million having been invested to engineer synthetic peptides with unique properties for the treatment of cancer. Pre-clinical results indicate CyPep-01, can be a ‘game changer’ in the €10 billion+ cancer market, offering a potentially new treatment where no satisfactory options currently exist.